To identify the energy source driving the enhanced mitochondrial metabolism caused by SLC44A2 knockdown, we treated control and SLC44A2-knockdown CRC cells with specific inhibitors targeting glycolysis, fatty acid oxidation (FAO), and glutaminolysis. The gene discussed is SLC44A2; the disease is colorectal carcinoma.